Menlo Park, CA, United States of America

Samuel S Gross

This inventor holds 15 USPTO granted patents and 23 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Cancer Detection. Top assignee: Grail, Inc.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Samuel S Gross. Retrieved from https://idiyas.com/inventor/samuel-s-gross

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 23)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 15)

EPO Patents = 5 (Patent Applications = 23)

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 21(Granted Patents)

Location History:

Menlo Park, CA (US) (2022 - 2024)
Sunnyvale, CA (US) (2023 - 2024)

Company Filing History:

15 out of 67

Grail, Inc.

patents

Years Active: 2022-2026

Loading Chart...

Areas of Expertise:

Cancer Classification

Genomic Region Modeling

Tumor Fraction Estimation

Methylation Markers

Contamination Markers

Cell-Free DNA

Anomalous Fragment Detection

Patient Classification

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12763163 - Cancer classification with genomic region modeling (2026-10-13),

2. 12688905 - METHOD AND SYSTEM OF CANCER DETECTION USING CPG-SNP CONTAMINATION MARKERS (2026-07-21),

3. 12497662 - Systems and methods for tumor fraction estimation from small variants (2025-12-16),

4. 12435375 - Methylation markers and targeted methylation probe panel (2025-10-07),

5. 12410482 - Methylation markers and targeted methylation probe panel (2025-09-09),

6. 12234514 - Source of origin deconvolution based on methylation fragments in cell-free DNA samples (2025-02-25),

7. 12191000 - Systems and methods for classifying patients with respect to multiple cancer classes (2025-01-07),

8. 12027237 - Anomalous fragment detection and classification (2024-07-02),

9. 12024750 - Methylation markers and targeted methylation probe panel (2024-07-02),

10. 11795513 - Methylation markers and targeted methylation probe panel (2023-10-24),

11. 11773450 - Methylation-based false positive duplicate marking reduction (2023-10-03),

12. 11725251 - Methylation markers and targeted methylation probe panel (2023-08-15),

13. 11685958 - Methylation markers and targeted methylation probe panel (2023-06-27),

14. 11581062 - Systems and methods for classifying patients with respect to multiple cancer classes (2023-02-14),

15. 11410750 - Methylation markers and targeted methylation probe panel (2022-08-09),

Title: The Innovations of Samuel S. Gross

Introduction

Samuel S. Gross is a prominent inventor based in Menlo Park, California. He has made significant contributions to the field of cancer diagnostics, holding a total of 12 patents. His work focuses on the development of innovative cancer assay panels that utilize methylation markers for targeted detection of cancer-specific patterns.

Latest Patents

Among his latest patents is a cancer assay panel designed for the targeted detection of cancer-specific methylation patterns. This patent outlines methods for designing, making, and using the cancer assay panel for the diagnosis of cancer. The advancements in this area are crucial for improving cancer detection and treatment strategies.

Career Highlights

Samuel S. Gross is currently associated with Grail, Inc., a company dedicated to advancing cancer detection technologies. His expertise in methylation markers has positioned him as a key player in the field of cancer diagnostics.

Collaborations

He has collaborated with notable colleagues, including Oliver Claude Venn and Seyedmehdi Shojaee, contributing to the innovative research and development at Grail, Inc.

Conclusion

Samuel S. Gross continues to push the boundaries of cancer diagnostics through his innovative patents and collaborations. His work is instrumental in the ongoing fight against cancer, paving the way for more effective detection methods.

Profile summary based on public USPTO records.